Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0011570 (depression)
 172,036 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

Female patients with the menopausal syndrome (MS) manifestations showed a steeper increment of diastolic arterial blood pressure (ABP) and heart rate, as compared to normal subjects, in both phases of the menopause, irrespective of whether cardialgia was present or not; moreover, half of the patients showed negative electrocardiographic dynamics. Hemodynamic shifts in response to bicycle ergometry were similar in both menopausal phases and showed steeper increments in ABP and heart rate, as compared to those of normal subjects. Excessive ABP rise in response to exercise is mostly associated with cardialgias. Exercise-related ECG can usually improve or return to normal in premenopausal patients, while ischemic ST depression is associated with postmenopausal conditions. Physical working capacity of premenopausal women is only impaired in the presence of cardialgias, whereas that of postmenopausal women is reduced in the absence of cardialgia as well.
 ...
PMID:[Circulatory system reaction to loading tests in patients with the climacteric syndrome in relation to the phase of the climacteric and the presence of cardialgia]. 399 23

A group of 78 women with sudden flushes and associated disorders (pruritus vulvae, headache, anxiety, instability, depression, libido disturbances) related to the menopause were treated with one or two capsules of veralipride daily for 20 days. Excellent or good results were obtained in 54 of the 69 patients (78 p. cent) with sudden flushes, and 29 of the 57 cases (51 p. cent) with associated disorders. The difference in scores before and after treatment is very highly significant (p < 0.001). Clinical tolerance was good as only 2 cases of minimal galactorrhea. 2 cases of mastodynia, 3 cases with mild drowsiness, 2 patients with nervous tension or insomnia, 3 with digestive disorders, 1 with vertigo, and 1 with mild visual disturbances were observed. No modifications in the biological parameters studied were noted. Blood prolactin levels increased during treatment but returned to normal levels 4 days after discontinuation of therapy. No significant modifications in FSH, LH, E2, or E3 plasma levels were noted at the end of the study. Veralipride appears, therefore, to be the prototype for non-hormonal therapy of menopausal disorders.
 ...
PMID:[A new therapeutic approach to menopausal sudden flushes and psychofunctional disorders (author's transl)]. 625 60

We studied a case of surgical menopause in a hysterical patient. Castration was followed by depression with sexual disorders, somatic complaints, and specific menopausal manifestations, mainly hot flushes. Hysterectomy had been done a year earlier. Since then the patient had been admitted twice to a psychiatric ward following attempted suicide. Veralipride was given for twenty days. Noticeable improvement was recorded. Therapy was then discontinued for ten days. Symptoms recurred and long-lasting therapy was decided on. Subsequently, sustained overall improvement with disappearance of specific menopausal disorders, were recorded.
 ...
PMID:[Intractable menopausal disorders cured by veralipride (author's transl)]. 627 94

At the time of menopause, some women present with a clinical picture that has not only the specificity of estrogen deficiency, such as hot flushes, but also a nonspecific psychologic syndrome characterized largely by anxiety and depression. Both the physiology of aging and environmental stress factors unique to this age contribute to psychologic changes. Estrogen deficiency can further aggravate these psychologic changes. This effect of estrogen lack is mediated or modulated by catecholamines and prostaglandins at the level of the central nervous system. The conceptualization of the magnitude of contributions to psychologic changes occurring at menopause is shown in Figure 2. The therapeutic principle that emerges from this review is that the psychologic aspects of the menopausal syndrome should be treated as any other anxiety or depressive reaction and that only when the relief is persistently incomplete, showing unequivocally the predominance of estrogen deficiency, should replacement hormone therapy be considered.
 ...
PMID:Age, Estrogens, and the psyche. 701 35

The incidence of climacteric symptoms was determined in 247 healthy premenopausal women in a community setting. These volunteers had been recruited to a longitudinal study of bone density. Of these subjects, 46 ceased to menstruate during the study, and in this subgroup symptoms were compared before and after cessation of menstruation. Only hot flushes increased after cessation of menstruation in the longitudinal study and showed age correlation in the cross-sectional study. Hot flushes thus emerged as a true menopausal symptom. Although evidence for this is weaker, cold sweats and suffocation seem likely to be genuinely menopausal. Breast discomfort and the four mood symptoms of irritability, excitability, depression and poor concentration improved after cessation of menstruation, and this study gives no support for their being part of the menopausal syndrome; it suggests that these symptoms are more likely to be related to menstruation than to the menopause.
 ...
PMID:Climacteric symptoms in healthy middle-aged women. 791 16

The various symptoms that women experience in the climacteric period, such as flashing, depression, paresthesia and insomnia, have been termed the menopausal syndrome. Since Kamikihi-to (KMK) has been administered clinically for several of these symptoms, the effects of KMK were evaluated in a series of experiments using adult ovariectomized (OVX) rats. After surgery, KMK and other drugs were administered daily for 7 or 8 days until the experiments. OVX rats showed significantly higher electric shock thresholds, and KMK restored their sensitivity to electric shock in a dose-dependent manner. Furthermore, the latency of OVX rats in the step-through passive avoidance test was significantly shortened, and KMK prolonged the latency significantly. OVX rats showed a significantly decreased number of correct choices and an increased number of errors in the 8-arm radial maze task, and KMK normalized both of these parameters in a dose-dependent manner. The blood pressure of OVX rats was significantly increased, and KMK improved the blood pressure levels. These findings suggest that KMK might be useful for treatment of the menopausal syndrome, and it is considered that the improvements induced by KMK are due to other actions, such as normalization of the central nervous system, rather than sex hormones.
 ...
PMID:[Effects of kamikihi-to on ovariectomy-induced changes in behavior and circulation in rats]. 882 24

Pomegranate is known to contain estrogens (estradiol, estrone, and estriol) and show estrogenic activities in mice. In this study, we investigated whether pomegranate extract is effective on experimental menopausal syndrome in ovariectomized mice. Prolongation of the immobility time in forced swimming test, an index of depression, was measured 14 days after ovariectomy. The bone mineral density (BMD) of the tibia was measured by X-ray absorptiometry and the structure and metabolism of bone were also analyzed by bone histomorphometry. Administration of pomegranate extract (juice and seed extract) for 2 weeks to ovariectomized mice prevented the loss of uterus weight and shortened the immobility time compared with 5% glucose-dosed mice (control). In addition, ovariectomy-induced decrease of BMD was normalized by administration of the pomegranate extract. The bone volume and the trabecular number were significantly increased and the trabecular separation was decreased in the pomegranate-dosed group compared with the control group. Some histological bone formation/resorption parameters were significantly increased by ovariectomy but were normalized by administration of the pomegranate extract. These changes suggest that the pomegranate extract inhibits ovariectomy-stimulated bone turnover. It is thus conceivable that pomegranate is clinically effective on a depressive state and bone loss in menopausal syndrome in women.
 ...
PMID:Pomegranate extract improves a depressive state and bone properties in menopausal syndrome model ovariectomized mice. 1509 54

Moexipril was given to 35 postmenopausal women with mild and moderate hypertension, menopausal syndrome and decreased bone mineral density. Blood pressure (BP) was measured before and in 1, 3, 6, and 12 months, while ultrasonic bone densitometry was carried out before and in 12 months of moexipril use. Significant lowering of systolic and diastolic BP, reduction of severity of climacteric syndrome occurred after 1, 3 and 6 months of moexipril use, respectively. After 12 months parameters of bone densitometry in moexipril treated women became better than in control group (p<0.01). Treatment was also associated with significant improvement of quality of life, diminished reactive anxiety and depression.
 ...
PMID:[The use of moexipril in postmenopausal women with hypertension and associated changes of bone mineral density]. 1609 58

A variety of symptoms are reported frequently as being part of a menopausal syndrome. These include hot flashes, night sweats, menstrual irregularities, vaginal dryness, depression, nervous tension, palpitations, headaches, insomnia, lack of energy, difficulty concentrating, and dizzy spells. The question of whether and how symptoms occur together is important for women who want to know which symptoms can be attributed to menopause and which to aging generally or to other physical or psychosocial factors. To address this question, the present article examines the following avenues of research: (1) the clustering or grouping of symptoms; (2) the temporal association of different symptoms with stages of the menopausal transition; (3) the consistency of symptom reporting across cultures, race, and ethnicity; and (4) the consistency of risk factors for symptoms. Results of the factor analysis studies do not support a single syndrome consisting of menopausal and psychological or somatic symptoms. The prevalence of symptom reporting across the transition also argues against a menopausal syndrome because vasomotor symptoms follow a unique pattern that differs from that of other symptoms. Cross-cultural differences suggest that symptom reporting is not universal. Finally, although there is some overlap in risk factors for symptoms, menopausal status is more consistently related to vasomotor symptoms than to psychological or physical ones. Results of these investigations all argue against a universal menopausal syndrome. Future research should focus on how symptoms are interrelated, what factors are uniquely related to vasomotor symptoms, and identifying whether there is a subgroup of women who are more likely to report symptoms.
 ...
PMID:A universal menopausal syndrome? 1641 25

This article revisits the links between psychopathology and functional gastrointestinal disorders such as irritable bowel syndrome (IBS), discusses the rational use of antidepressants as well as non-pharmacological approaches to the management of IBS, and suggests guidelines for the treatment of IBS based on an interdisciplinary perspective from the present state of knowledge. Relevant published literature on psychiatric disorders, especially somatization disorder, in the context of IBS, and literature providing direction for management is reviewed, and new directions are provided from findings in the literature. IBS is a heterogeneous syndrome with various potential mechanisms responsible for its clinical presentations. IBS is typically complicated with psychiatric issues, unexplained symptoms, and functional syndromes in other organ systems. Most IBS patients have multiple complaints without demonstrated cause, and that these symptoms can involve systems other than the intestine, e.g. bones and joints (fibromyalgia, temporomandibular joint syndrome), heart (non-cardiac chest pain), vascular (post-menopausal syndrome), and brain (anxiety, depression). Most IBS patients do not have psychiatric illness per se, but a range of psychoform (psychological complaints in the absence of psychiatric disorder) symptoms that accompany their somatoform (physical symptoms in the absence of medical disorder) complaints. It is not correct to label IBS patients as psychiatric patients (except those more difficult patients with true somatization disorder). One mode of treatment is unlikely to be universally effective or to resolve most symptoms. The techniques of psychotherapy or cognitive-behavioral therapy can allow IBS patients to cope more readily with their illness. Specific episodes of depressive or anxiety disorders can be managed as appropriate for those conditions. Medications designed to improve anxiety or depression are not uniformly useful for psychiatric complaints in IBS, because the psychoform symptoms that sound similar to those seen in psychiatric disorders may not have the same significance in patients with IBS.
 ...
PMID:Relationship of functional gastrointestinal disorders and psychiatric disorders: implications for treatment. 1746 42


1 2 Next >>